Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mepazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 known ✓ | Q9UDY8 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 3/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 3/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mepazine SCHEMBL17746928 | 1.00 | CHRM2 (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Mepazine SCHEMBL31281799 | 1.00 | CHRM2 (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Mepazine SCHEMBL17756664 | 1.00 | CHRM2 (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Mepazine SCHEMBL29436812 | 1.00 | CHRM2 (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Mepazine SCHEMBL5058441 | 0.99 | CHRM2 (0.97) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Mepazine SCHEMBL1651268 | 0.97 | CHRM2 (0.95) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Mepazine SCHEMBL5063632 | 0.92 | GFER (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Mepazine SCHEMBL31238126 | 0.92 | GFER (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Methdilazine SCHEMBL29415150 | 0.91 | CYP2D6 (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 | |
| Methdilazine SCHEMBL121507 | 0.91 | CYP2D6 (1.00) | CHRM2ADRA2ACHRM1DRD1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 588 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025073968-A1 | COMBINATION OF ROGINOLISIB WITH A MALT1-GLS INHIBITOR | IONCTURA SA (CH) | 2025-04-10 | — | — | WO | claimed |
| EP-4525870-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | Corcept Therapeutics Incorporated (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4001275-B1 | (S)-ENANTIOMER OF MEPAZINE AS PARACASPASE (MALT1) INHIBITOR FOR THE TREATMENT OF CANCER | HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM GESUNDHEIT & UMWELT GMBH (DE) | 2024-11-27 | — | — | EP | claimed |
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2024-07-25 | — | — | US | claimed |
| US-20240217961-A1 | (S)-Mepazine Salt Forms, Process of Preparing, and Formulations Thereof | SHANGHAI STA PHARMACEUTICAL R&D CO., LTD. (CN) | 2024-07-04 | — | — | US | claimed |
| US-20240026461-A1 | BCL10 MUTATIONS AS BIOMARKERS FOR TARGETED THERAPY IN B CELL LYMPHOMAS | MELNICK ARI (US) | 2024-01-25 | — | — | US | claimed |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MONOPTEROS THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | US | claimed |
| WO-2023225282-A1 | METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-11-23 | — | — | WO | claimed |
| EP-4243812-A1 | MATERIALS AND METHODS OF TREATING CANCER | Monopteros Therapeutics, Inc. (US) | 2023-09-20 | — | — | EP | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| CN-1484525-A | Combinations of drugs (E. G chlorpromazine and pentamidine) for the treatment of neoplastic disorders | — | 2004-03-24 | — | — | CN | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| EP-1368008-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF PARTIAL DOPAMINE-D2 AGONISTS | LTS Lohmann Therapie-Systeme AG (DE) | 2003-12-10 | — | — | EP | claimed |
| EP-1339399-A2 | COMBINATIONS OF DRUGS (E.G., CHLORPROMAZINE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | Combinatorx, Incorporated (US) | 2003-09-03 | — | — | EP | claimed |
| WO-2002069941-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE ADMINISTRATION OF PARTIAL DOPAMINE-D2 AGONISTS | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2002-09-12 | — | — | WO | claimed |
| WO-2002058684-A2 | COMBINATIONS OF DRUGS (E.G., CHLORPROMAZINE AND PENTAMIDINE) FOR THE TREATMENT OF NEOPLASTIC DISORDERS | COMBINATORX, INCORPORATED (US) | 2002-08-01 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245659-A1 | Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | MALT1 308/4885CHRM2 3867/4885ADRA2A 589/4885 |
| US-20230372312-A1 | Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient | CYP3A43, NR3C2, CYP3A5 | MALT1 308/4885CHRM2 3867/4885ADRA2A 589/4885 |
| US-20240217961-A1 | (S)-Mepazine Salt Forms, Process of Preparing, and Formulations Thereof | MEP1A, MEP1B, IL5 | MALT1 1548/4885CHRM2 214/4885ADRA2A 678/4885 |
| US-20230414629-A1 | MATERIALS AND METHODS OF TREATING CANCER | MALT1, TP53, RAD1 | MALT1 1/4885CHRM2 4840/4885ADRA2A 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.